Citi upgraded BioAge Labs (BIOA) to Buy from Neutral with a price target of $10, up from $5. The firm believes the company’s BGE-102 can become a “differentiated” NLRP3 inhibitor in treating obesity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA: